Clinical Trial Update: A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and immunologic response of COMBIG-DC in patients with metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• COMBIG-DC

Snippet

Sponsor: Mendus | Conditions: Metastatic Renal Cell Carcinoma | Phase 1 | Status: COMPLETED